HLS Therapeutics Inc. (HLTRF)
- Previous Close
2.9000 - Open
2.9200 - Bid --
- Ask --
- Day's Range
2.9200 - 2.9200 - 52 Week Range
2.6000 - 4.9494 - Volume
500 - Avg. Volume
174 - Market Cap (intraday)
92.898M - Beta (5Y Monthly) 1.09
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8600 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield 0.15 (4.21%)
- Ex-Dividend Date Apr 27, 2023
- 1y Target Est
--
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
www.hlstherapeutics.com91
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: HLTRF
Performance Overview: HLTRF
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HLTRF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HLTRF
Valuation Measures
Market Cap
89.88M
Enterprise Value
155.54M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.54
Price/Book (mrq)
1.04
Enterprise Value/Revenue
2.56
Enterprise Value/EBITDA
14.28
Financial Highlights
Profitability and Income Statement
Profit Margin
-45.81%
Return on Assets (ttm)
-3.08%
Return on Equity (ttm)
-26.78%
Revenue (ttm)
60.79M
Net Income Avi to Common (ttm)
-27.84M
Diluted EPS (ttm)
-0.8600
Balance Sheet and Cash Flow
Total Cash (mrq)
19.44M
Total Debt/Equity (mrq)
95.54%
Levered Free Cash Flow (ttm)
22.53M
Company Insights: HLTRF
HLTRF does not have Company Insights